

Andrew D Kelly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4951715/publications.pdf>

Version: 2024-02-01

11
papers

319
citations

1307594

7
h-index

1372567

10
g-index

13
all docs

13
docs citations

13
times ranked

610
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. <i>Genome Medicine</i> , 2013, 5, 2.	8.2	96
2	Metabolomic Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Targeted LC/MS/MS: Application in Sarcoma. <i>PLoS ONE</i> , 2011, 6, e25357.	2.5	70
3	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. <i>Journal of Hematology and Oncology</i> , 2017, 10, 107.	17.0	38
4	MicroRNA-155 expression is independently predictive of outcome in chordoma. <i>Oncotarget</i> , 2015, 6, 9125-9139.	1.8	38
5	Next-generation sequencing and microarray-based interrogation of microRNAs from formalin-fixed, paraffin-embedded tissue: Preliminary assessment of cross-platform concordance. <i>Genomics</i> , 2013, 102, 8-14.	2.9	27
6	Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 106.	4.1	21
7	Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma. <i>Communications Biology</i> , 2022, 5, 213.	4.4	10
8	Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
9	A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study. <i>BMC Genomics</i> , 2012, 13, 332.	2.8	3
10	Epigenetics and Cancer. <i>Energy Balance and Cancer</i> , 2016, , 1-28.	0.2	2
11	STRN-ALK Fusionâ€“Positive Case of Breast Cancer With Response to Alectinib. <i>JCO Precision Oncology</i> , 2021, 5, 1281-1284.	3.0	2